Oncolys BioPharma Inc. announced that it has received a notice from Transposon Therapeutics Inc., licensee of OBP-601 (censavudine, TPN-101), that enrollment has been completed with 42 patients randomized in the Phase IIa, double-blind, placebo- controlled study of OBP-601 in patients with Progressive Supranuclear Palsy (PSP). The target date for publication of the clinical trial results has not yet been determined. In addition, the Phase IIa, double-blind, placebo-controlled study in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD) is recruiting patients.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
622 JPY | -4.16% | -11.90% | +9.70% |
1st Jan change | Capi. | |
---|---|---|
+9.70% | 86.8M | |
-3.15% | 89.69B | |
+2.50% | 41.34B | |
-12.01% | 33.72B | |
+62.74% | 26.11B | |
-19.79% | 14.63B | |
-8.58% | 12.84B | |
-12.34% | 11.66B | |
-43.92% | 11.52B | |
+4.27% | 8.92B |
- Stock Market
- Equities
- 4588 Stock
- News Oncolys BioPharma Inc.
- Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with Progressive Supranuclear Pals